ImmuneMed, Inc.
- Country
- ๐ฐ๐ทSouth Korea
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.immunemed.co.kr
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)โข Click on a phase to view related trials
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06306339
- Locations
- ๐ณ๐ฑ
University Medical Center Urtrecht, Utrecht, GA, Netherlands
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Standard of care
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05808335
- Locations
- ๐ฐ๐ท
Chung-Ang University Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo (intravenous, single dose)Drug: hzVSF-v13 (intravenous, single dose)Drug: hzVSF-v13 (intravenous, multiple dose)Drug: hzVSF-v13 (subcutaneous, single dose)Drug: Placebo (intravenous, multiple dose)Drug: Placebo (subcutaneous, single dose)
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04817202
- Locations
- ๐ฆ๐บ
CMAX, Clinical Research Pty Ltd., Adelaide, South Australia, Australia
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04679415
- Locations
- ๐ฎ๐ฉ
Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
๐ฎ๐ฉRumah Sakit Pasar Minggu, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
๐ฎ๐ฉRumah Sakit Umum Persahabatan, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04679350
- Locations
- ๐ฐ๐ท
Yeungnam University Medical Center, Daegu, Korea, Republic of
๐ฐ๐ทKeimyung University Dongsan Hospital, Daegu, Korea, Republic of
๐ฐ๐ทChungnam National University Hospital, Daejeon, Korea, Republic of
- Prev
- 1
- 2
- Next